Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Acura Pharmaceuticals, Inc. (ACUR)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Drug Manufacturers - Specialty & Generic
Address
616 N. North Court 60067
Palatine, IL, US
Palatine, IL, US
CEO
Robert Jones
Website
acurapharm.com
IPO
1986-03-28
CIK 786947 ISIN US00509L8028
Description
Acura Pharmaceuticals, Inc. operates as a drug delivery innovator, dedicated to exploring, developing, and bringing to market novel technologies and products aimed at enhancing medication safety across the United States. Its product portfolio features Oxaydo tablets, a potent Schedule II narcotic prescribed for managing both acute and chronic moderate-to-severe pain. The company also offers the Nexafed line, consisting of pseudoephedrine and acetaminophen tablets, widely utilized as nasal decongestants in a range of over-the-counter and prescription formulations for cold, sinus, and allergy relief. Beyond its current offerings, Acura is actively advancing six additional opioid products through various stages of formulation development. To support its global reach, Acura Pharmaceuticals maintains strategic collaboration and licensing agreements with Egalet US, Inc. and Egalet Ltd. for the worldwide production and commercialization of its Oxaydo products. Furthermore, it has established a development and commercialization partnership with Abuse Deterrent Pharma, LLC to create LTX-03, an immediate-release tablet leveraging the proprietary LIMITx technology. Established in 1935, the company's operations are headquartered in Palatine, Illinois.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1.2K
Beta
-54.49
Float Shares
64.20M
Free Float %
97.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -60.00% | -60.00% | +0.00% | -60.00% | -99.00% | -99.60% | -99.95% | -99.99% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (3 ratings, all time)
Buy
Price Targets & DCF
Current price
0.00
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-635.99
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
2 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-56.2% Q4'21: -95.0% (vs Q4'20)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+58.6% ★ Q4'21: +103.6% (vs Q4'20)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-20.0% Q4'21: -1,183.3% (vs Q4'20)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-43.4% Q4'21: +80.6% (vs Q4'20)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-216.9% Q4'21: +37.1% (vs Q4'20)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+75.8% Q4'21: +133.6% (vs Q4'20)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.34× Q4'21: 1.06× (vs Q4'20)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
|---|---|---|---|---|---|---|---|
| Revenue |
2.97M
est: 2.18M (+35.9%)
|
410.0K
est: 31.70M (-98.7%)
|
2.66M
est: 10.04M (-73.5%)
|
3.57M
est: 9.39M (-62.0%)
|
1.56M
est: 8.78M (-82.2%)
|
8.21M
est.
|
7.68M
est.
|
| EBITDA |
-4.93M
est: -4.49M (-9.7%)
|
-3.17M
est: -4.20M (+24.6%)
|
-3.04M
est: -3.93M (+22.6%)
|
-633.0K
est: -3.67M (+82.8%)
|
-589.0K
est: -3.43M (+82.8%)
|
-3.21M
est.
|
-3.00M
est.
|
| EBIT |
-5.22M
est: -5.02M (-4.0%)
|
-3.45M
est: -4.69M (+26.6%)
|
-3.31M
est: -4.39M (+24.5%)
|
-758.0K
est: -4.10M (+81.5%)
|
-679.0K
est: -3.84M (+82.3%)
|
-3.59M
est.
|
-3.35M
est.
|
| Net Income |
-5.68M
est: -5.95M (+4.5%)
|
-3.84M
est: -5.57M (+31.0%)
|
-3.77M
est: -5.20M (+27.5%)
|
-1.21M
est: -4.87M (+75.2%)
|
-879.0K
est: -4.55M (+80.7%)
|
-4.25M
est.
|
-3.98M
est.
|
| SGA |
4.34M
est: 4.34M (+0.0%)
|
2.57M
est: 7.32M (-64.9%)
|
1.88M
est: 6.84M (-72.6%)
|
2.55M
est: 6.40M (-60.2%)
|
1.25M
est: 5.98M (-79.0%)
|
5.59M
est.
|
5.23M
est.
|
| EPS |
-0.36
|
-0.18
|
-0.14
est: -0.77 (+81.7%)
|
-0.04
est: -0.72 (+94.4%)
|
-0.02
est: -0.68 (+97.1%)
|
-0.64
est.
|
-0.61
est.
|
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-1.13M
OE per share TTM
-0.03
Owner's Yield
-7,443.11%
Maintenance CapEx ratio
449.32%
Maint CapEx / Avg PPE
19.1%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
13
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | John Schutte | 10.70M | 47.50% | 10.70M | — | 10.70M | — | IN | United States | 2017-08-03 | ↗ |
| 2 | Sabby Healthcare Master Fund, Ltd. | 4.66M | 7.90% | — | 4.66M | — | 4.66M | CO | Cayman Islands | 2015-07-09 | ↗ |
| 3 | Care Capital II, LLC | 3.33M | 6.80% | — | 3.33M | — | 10.00 | OO | Delaware | 2015-03-09 | ↗ |
| 4 | Care Capital Investments II, LP | 3.11M | 6.40% | — | 3.11M | — | 10.00 | PN | Delaware | 2015-03-09 | ↗ |
| 5 | Deerfield Management Company, L.P. | 1.03M | 8.67% | — | 1.03M | — | — | PN | Delaware | 2017-02-14 | ↗ |
| 6 | Deerfield Special Situations Fund, L.P. | 1.03M | 8.67% | — | 1.03M | — | — | PN | Delaware | 2017-02-14 | ↗ |
| 7 | ================================================================ | 875.9K | 6.08% | 875.9K | — | 875.9K | — | IN | ================================================================ | 1998-12-18 | ↗ |
| 8 | PETER ZUELLIG | 639.2K | 5.40% | — | 639.2K | — | 639.2K | IN | SCHEDULE 13D | 1997-02-12 | ↗ |
| 9 | Care Capital Offshore Investments II, LP | 213.5K | 0.40% | — | 213.5K | — | 10.00 | PN | Cayman Islands | 2015-03-09 | ↗ |
| 10 | Company, L.P. | — | 0.00% | — | — | — | — | PN | Delaware | 2018-02-14 | ↗ |
| 11 | Deerfield Mgmt, L.P. | — | 0.00% | — | — | — | — | PN | Delaware | 2018-02-14 | ↗ |
| 12 | James E. Flynn | — | 0.00% | — | — | — | — | IN | Delaware | 2018-02-14 | ↗ |
| 13 | Situations Fund, L.P. | — | 0.00% | — | — | — | — | PN | Delaware | 2018-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.50
Neutral
Ratio by volume
0.54
Neutral
Buys
4
Sells
8
Shares acquired
187.5K
Shares disposed
350.0K
Cash buys
—
Cash sales
—
Net activity
-162,500
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-02 | THANGARAJ IMMANUEL | Director | M-Exempt | A | Common Stock | 50,000 | 0.01 | 500.00 | 547,647 | D | ↗ |
| 2026-01-02 | SKELLY WILLIAM G | Director | M-Exempt | A | Common Stock | 50,000 | 0.01 | 500.00 | 675,989 | D | ↗ |
| 2026-01-02 | ROSS GEORGE K | Director | M-Exempt | A | Common Stock | 50,000 | 0.01 | 500.00 | 595,903 | D | ↗ |
| 2025-01-02 | THANGARAJ IMMANUEL | Director | M-Exempt | D | Restricted Stock Units (2021 Plan) | 50,000 | 0.00 | — | 0 | D | ↗ |
| 2025-01-02 | SKELLY WILLIAM G | Director | A-Award | D | Restricted Stock Units (2021 Plan) | 50,000 | 0.00 | — | 50,000 | D | ↗ |
| 2025-01-02 | ROSS GEORGE K | Director | M-Exempt | D | Restricted Stock Units (2021 Plan) | 50,000 | 0.00 | — | 0 | D | ↗ |
| 2024-01-02 | WESSON BRUCE F | Director | D-Return | D | Restricted Stock Units (2021 Plan) | 12,500 | 0.00 | — | 0 | — | ↗ |
| 2024-01-02 | THANGARAJ IMMANUEL | Director | M-Exempt | D | Restricted Stock Units (2021 Plan) | 50,000 | 0.00 | — | 0 | — | ↗ |
| 2024-01-02 | SKELLY WILLIAM G | Director | M-Exempt | D | Restricted Stock Units (2021 Plan) | 50,000 | 0.00 | — | 0 | — | ↗ |
| 2024-01-02 | ROSS GEORGE K | Director | M-Exempt | D | Restricted Stock Units (2021 Plan) | 50,000 | 0.00 | — | 0 | — | ↗ |
| 2023-11-20 | Seiser Robert A | Officer | M-Exempt | A | Restricted Stock Unit (2021 Plan) | 40,000 | 0.01 | 400.00 | 0 | — | ↗ |
| 2023-11-20 | Jones Robert B | Officer | M-Exempt | D | Restricted Stock Unit (2021 Plan) | 40,000 | 0.01 | 400.00 | 0 | — | ↗ |
| 2023-11-20 | CLEMENS PETER A | Officer | M-Exempt | A | Common Stock | 40,000 | 0.01 | 400.00 | 545,430 | — | ↗ |
| 2023-11-20 | Brzeczko Albert W | Officer | M-Exempt | A | Restricted Stock Unit (2021 Plan) | 40,000 | 0.01 | 400.00 | 0 | — | ↗ |
| 2023-01-03 | WESSON BRUCE F | Director | M-Exempt | D | Restricted Stock Units (2021 Plan) | 66,666 | 0.00 | — | 0 | — | ↗ |
| 2023-01-03 | THANGARAJ IMMANUEL | Director | M-Exempt | D | Restricted Stock Units (2021 Plan) | 66,666 | 0.00 | — | 0 | — | ↗ |
| 2023-01-03 | Seiser Robert A | Officer | M-Exempt | A | Restricted Stock Unit (2017 Plan) | 20,000 | 0.00 | — | 40,000 | — | ↗ |
| 2023-01-03 | SKELLY WILLIAM G | Director | M-Exempt | D | Restricted Stock Units (2021 Plan) | 66,666 | 0.00 | — | 0 | — | ↗ |
| 2023-01-03 | ROSS GEORGE K | Director | A-Award | D | Restricted Stock Units (2021 Plan) | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2023-01-03 | Jones Robert B | Officer | M-Exempt | A | Restricted Stock Unit (2017 Plan) | 50,000 | 0.00 | — | 40,000 | — | ↗ |
| 2023-01-03 | CLEMENS PETER A | Officer | M-Exempt | A | Restricted Stock Unit (2017 Plan) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2023-01-03 | Brzeczko Albert W | Officer | M-Exempt | A | Restricted Stock Unit (2017 Plan) | 34,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-08-03 | Seiser Robert A | Officer | M-Exempt | A | Restricted Stock Unit (2017 Plan) | 4,666 | 0.00 | — | 80,000 | — | ↗ |
| 2022-08-03 | Jones Robert B | Officer | M-Exempt | A | Restricted Stock Unit (2017 Plan) | 13,666 | 0.01 | 136.66 | 140,000 | — | ↗ |
| 2022-08-03 | CLEMENS PETER A | Officer | M-Exempt | A | Restricted Stock Unit (2017 Plan) | 40,000 | 0.01 | 400.00 | 80,000 | — | ↗ |
| 2022-08-03 | Brzeczko Albert W | Officer | M-Exempt | A | Common Stock | 43,333 | 0.00 | — | 412,001 | — | ↗ |
| 2022-03-16 | Seiser Robert A | Officer | A-Award | A | Restricted Stock Unit | 40,000 | 0.00 | — | 84,666 | — | ↗ |
| 2022-03-16 | Jones Robert B | Officer | A-Award | A | Restricted Stock Unit | 40,000 | 0.01 | 400.00 | 153,666 | — | ↗ |
| 2022-03-16 | CLEMENS PETER A | Officer | A-Award | A | Restricted Stock Unit | 40,000 | 0.00 | — | 129,333 | — | ↗ |
| 2022-03-16 | Brzeczko Albert W | Officer | A-Award | A | Restricted Stock Unit | 40,000 | 0.01 | 400.00 | 117,332 | — | ↗ |
| 2022-01-03 | WESSON BRUCE F | Director | M-Exempt | D | Restricted Stock Units (2021 Plan) | 66,666 | 0.00 | — | 0 | — | ↗ |
| 2022-01-03 | THANGARAJ IMMANUEL | Director | M-Exempt | D | Restricted Stock Units (2021 Plan) | 66,666 | 0.00 | — | 0 | — | ↗ |
| 2022-01-03 | SKELLY WILLIAM G | Director | M-Exempt | D | Restricted Stock Units (2021 Plan) | 66,666 | 0.00 | — | 0 | — | ↗ |
| 2022-01-03 | ROSS GEORGE K | Director | M-Exempt | A | Common Stock | 66,666 | 0.01 | 666.66 | 378,837 | — | ↗ |
| 2021-06-09 | Schutte John | 10% Owner | C-Conversion | D | Convertible Promissory Note | 0 | 0.16 | — | 0 | — | ↗ |
| 2021-06-09 | Abuse Deterrent Pharma, LLC | 10% Owner | C-Conversion | D | Convertible Promissory Note | 6,877,500 | 0.16 | 1.10M | 0 | — | ↗ |
| 2021-05-25 | WESSON BRUCE F | Director | A-Award | A | Restricted Stock Units (2021 Plan) | 66,666 | 0.00 | — | 66,666 | — | ↗ |
| 2021-05-25 | THANGARAJ IMMANUEL | Director | A-Award | A | Restricted Stock Units (2021 Plan) | 66,666 | 0.00 | — | 66,666 | — | ↗ |
| 2021-05-25 | SKELLY WILLIAM G | Director | A-Award | A | Restricted Stock Units (2021 Plan) | 66,666 | 0.00 | — | 66,666 | — | ↗ |
| 2021-05-25 | ROSS GEORGE K | Director | A-Award | A | Restricted Stock Units (2021 Plan) | 66,666 | 0.00 | — | 66,666 | — | ↗ |
| 2021-02-24 | Seiser Robert A | Officer | F-InKind | D | Common Stock | 7,550 | 0.40 | 3.0K | 353,588 | — | ↗ |
| 2021-02-24 | EMIGH JAMES F | Officer | F-InKind | D | Common Stock | 7,550 | 0.40 | 3.0K | 474,042 | — | ↗ |
| 2021-02-24 | CLEMENS PETER A | Officer | M-Exempt | D | Stock options | 40,000 | 0.15 | 6.0K | 0 | — | ↗ |
| 2021-01-04 | WESSON BRUCE F | Director | M-Exempt | D | Restricted Stock Units (2017 Plan) | 54,790 | 0.00 | — | 0 | — | ↗ |
| 2021-01-04 | THANGARAJ IMMANUEL | Director | M-Exempt | D | Restricted Stock Units (2017 Plan) | 54,790 | 0.00 | — | 0 | — | ↗ |
| 2021-01-04 | Seiser Robert A | Officer | M-Exempt | A | Restricted Stock Unit (2017 Plan) | 20,000 | 0.01 | 200.00 | 49,333 | — | ↗ |
| 2021-01-04 | SKELLY WILLIAM G | Director | M-Exempt | A | Common Stock | 54,790 | 0.01 | 547.90 | 392,657 | — | ↗ |
| 2021-01-04 | ROSS GEORGE K | Director | M-Exempt | A | Common Stock | 54,790 | 0.01 | 547.90 | 312,171 | — | ↗ |
| 2021-01-04 | Jones Robert B | Officer | M-Exempt | A | Restricted Stock Unit (2017 Plan) | 13,667 | 0.01 | 136.67 | 163,666 | — | ↗ |
| 2021-01-04 | EMIGH JAMES F | Officer | M-Exempt | A | Common Stock | 24,667 | 0.01 | 246.67 | 468,994 | — | ↗ |
| 2021-01-04 | CLEMENS PETER A | Officer | F-InKind | D | Common Stock | 19,514 | 0.21 | 4.1K | 391,197 | — | ↗ |
| 2021-01-04 | Brzeczko Albert W | Officer | M-Exempt | A | Common Stock | 43,334 | 0.01 | 433.34 | 368,668 | — | ↗ |
| 2020-01-02 | WESSON BRUCE F | Director | M-Exempt | A | Common Stock | 83,333 | 0.01 | 833.33 | 603,926 | — | ↗ |
| 2020-01-02 | THANGARAJ IMMANUEL | Director | M-Exempt | D | Restricted Stock Units (2017 Plan) | 83,333 | 0.00 | — | 0 | — | ↗ |
| 2020-01-02 | Seiser Robert A | Officer | M-Exempt | A | Restricted Stock Unit (2017 Plan) | 4,667 | 0.01 | 46.67 | 69,333 | — | ↗ |
| 2020-01-02 | SKELLY WILLIAM G | Director | M-Exempt | A | Common Stock | 83,333 | 0.01 | 833.33 | 337,867 | — | ↗ |
| 2020-01-02 | ROSS GEORGE K | Director | M-Exempt | A | Common Stock | 50,000 | 0.01 | 500.00 | 261,005 | — | ↗ |
| 2020-01-02 | Jones Robert B | Officer | M-Exempt | A | Restricted Stock Unit (2017 Plan) | 13,667 | 0.01 | 136.67 | 177,333 | — | ↗ |
| 2020-01-02 | EMIGH JAMES F | Officer | M-Exempt | A | Restricted Stock Unit (2017 Plan) | 4,667 | 0.01 | 46.67 | 69,333 | — | ↗ |
| 2020-01-02 | CLEMENS PETER A | Officer | M-Exempt | A | Restricted Stock Unit (2017 Plan) | 9,334 | 0.01 | 93.34 | 138,666 | — | ↗ |
| 2020-01-02 | Brzeczko Albert W | Officer | M-Exempt | A | Common Stock | 9,334 | 0.01 | 93.34 | 325,334 | — | ↗ |
| 2019-06-28 | Schutte John | 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-06-28 | Abuse Deterrent Pharma, LLC | 10% Owner | — | D | Convertible Promissory Note | 37,500,000 | 0.16 | 6.00M | 0 | — | ↗ |
| 2019-01-02 | WESSON BRUCE F | Director | M-Exempt | D | Restricted Stock Units (2017 Plan) | 66,666 | 0.00 | — | 0 | — | ↗ |
| 2019-01-02 | THANGARAJ IMMANUEL | Director | M-Exempt | D | Restricted Stock Units (2017 Plan) | 66,666 | 0.00 | — | 0 | — | ↗ |
| 2019-01-02 | SKELLY WILLIAM G | Director | M-Exempt | D | Restricted Stock Units (2017 Plan) | 66,666 | 0.00 | — | 0 | — | ↗ |
| 2019-01-02 | ROSS GEORGE K | Director | M-Exempt | D | Restricted Stock Units (2017 Plan) | 66,666 | 0.00 | — | 0 | — | ↗ |
| 2018-12-11 | Seiser Robert A | Officer | A-Award | A | Stock Option | 20,000 | 0.15 | 3.0K | 20,000 | — | ↗ |
| 2018-12-11 | Jones Robert B | Officer | A-Award | A | Stock Option | 50,000 | 0.15 | 7.6K | 50,000 | — | ↗ |
| 2018-12-11 | EMIGH JAMES F | Officer | A-Award | A | Stock Option | 20,000 | 0.15 | 3.0K | 20,000 | — | ↗ |
| 2018-12-11 | CLEMENS PETER A | Officer | A-Award | A | Stock Option | 40,000 | 0.15 | 6.0K | 40,000 | — | ↗ |
| 2018-12-11 | Brzeczko Albert W | Officer | A-Award | A | Stock Option | 34,000 | 0.15 | 5.1K | 34,000 | — | ↗ |
| 2018-01-02 | WESSON BRUCE F | Director | M-Exempt | D | Restricted Stock Units | 59,523 | 0.00 | — | 0 | — | ↗ |
| 2018-01-02 | THANGARAJ IMMANUEL | Director | D-Return | D | Restricted Stock Units | 23,809 | 0.00 | — | 0 | — | ↗ |
| 2018-01-02 | SKELLY WILLIAM G | Director | A-Award | A | Restricted Stock Units | 66,666 | 0.00 | — | 66,666 | — | ↗ |
| 2018-01-02 | ROSS GEORGE K | Director | M-Exempt | D | Restricted Stock Units (2014 Plan) | 82,774 | 0.00 | — | 0 | — | ↗ |
| 2017-12-14 | WESSON BRUCE F | Director | P-Purchase | A | Common Stock | 335,734 | 0.10 | 33.6K | 394,404 | — | ↗ |
| 2017-12-14 | Seiser Robert A | Officer | P-Purchase | A | Common Stock | 300,000 | 0.10 | 30.0K | 322,490 | — | ↗ |
| 2017-12-14 | SKELLY WILLIAM G | Director | P-Purchase | A | Common Stock | 100,000 | 0.10 | 10.0K | 128,345 | — | ↗ |
| 2017-12-14 | ROSS GEORGE K | Director | P-Purchase | A | Common Stock | 50,000 | 0.10 | 5.0K | 61,565 | — | ↗ |
| 2017-12-14 | Jones Robert B | Director / Officer | P-Purchase | A | Common Stock | 400,000 | 0.10 | 40.0K | 412,555 | — | ↗ |
| 2017-12-14 | EMIGH JAMES F | Officer | P-Purchase | A | Common Stock | 400,000 | 0.10 | 40.0K | 439,660 | — | ↗ |
| 2017-12-14 | CLEMENS PETER A | Officer | P-Purchase | A | Common Stock | 300,000 | 0.10 | 30.0K | 355,182 | — | ↗ |
| 2017-12-14 | CLAUDIUS LLC | — | S-Sale | D | Common Stock | 2,195,734 | 0.10 | 219.6K | 0 | — | ↗ |
| 2017-12-14 | Brzeczko Albert W | Officer | P-Purchase | A | Common Stock | 300,000 | 0.10 | 30.0K | 316,000 | — | ↗ |
| 2017-12-11 | Seiser Robert A | Officer | A-Award | A | Restricted Stock Units | 14,000 | 0.00 | — | 14,000 | — | ↗ |
| 2017-12-11 | Jones Robert B | Director / Officer | A-Award | A | Restricted Stock Units | 41,000 | 0.00 | — | 41,000 | — | ↗ |
| 2017-12-11 | EMIGH JAMES F | Officer | A-Award | A | Restricted Stock Units | 14,000 | 0.00 | — | 14,000 | — | ↗ |
| 2017-12-11 | CLEMENS PETER A | Officer | A-Award | A | Restricted Stock Units | 28,000 | 0.00 | — | 28,000 | — | ↗ |
| 2017-12-11 | Brzeczko Albert W | Officer | A-Award | A | Restricted Stock Units | 28,000 | 0.00 | — | 28,000 | — | ↗ |
| 2017-08-29 | Brzeczko Albert W | Officer | P-Purchase | A | Common Stock | 1,000 | 0.47 | 470.00 | 16,000 | — | ↗ |
| 2017-08-28 | Brzeczko Albert W | Officer | P-Purchase | A | Common Stock | 2,000 | 0.45 | 909.20 | 12,000 | — | ↗ |
| 2017-08-25 | Brzeczko Albert W | Officer | P-Purchase | A | Common Stock | 1,800 | 0.48 | 864.00 | 10,000 | — | ↗ |
| 2017-08-09 | Seiser Robert A | Officer | A-Award | A | Stock Options | 14,000 | 0.45 | 6.3K | 14,000 | — | ↗ |
| 2017-08-09 | Jones Robert B | Director / Officer | A-Award | A | Stock Options | 47,000 | 0.45 | 21.2K | 47,000 | — | ↗ |
| 2017-08-09 | EMIGH JAMES F | Officer | A-Award | A | Stock Options | 14,000 | 0.45 | 6.3K | 14,000 | — | ↗ |
| 2017-08-09 | CLEMENS PETER A | Officer | A-Award | A | Stock Options | 34,000 | 0.45 | 15.3K | 34,000 | — | ↗ |
| 2017-08-09 | Brzeczko Albert W | Officer | A-Award | A | Stock Options | 35,000 | 0.45 | 15.8K | 35,000 | — | ↗ |
| 2017-07-24 | Schutte John | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 8,912,655 | — | ↗ |
| 2017-02-07 | Seiser Robert A | Officer | M-Exempt | A | Common Stock | 1,166 | 0.92 | 1.1K | 23,311 | — | ↗ |
| 2017-01-03 | WESSON BRUCE F | Director | M-Exempt | A | Common Stock | 22,026 | 0.01 | 220.26 | 58,670 | — | ↗ |
| 2017-01-03 | THANGARAJ IMMANUEL | Director | A-Award | A | Restricted Stock Units | 59,523 | 0.00 | — | 59,523 | — | ↗ |
| 2017-01-03 | SKELLY WILLIAM G | Director | D-Return | D | Restricted Stock Units | 8,810 | 0.00 | — | 13,216 | — | ↗ |
| 2017-01-03 | ROSS GEORGE K | Director | M-Exempt | D | Restricted Stock Units | 735 | 0.00 | — | 0 | — | ↗ |
| 2016-12-08 | Seiser Robert A | Officer | A-Award | A | Stock Options | 14,000 | 0.92 | 12.8K | 14,000 | — | ↗ |
| 2016-12-08 | Rivet J Bradley | Officer | A-Award | A | Stock Options | 14,000 | 0.92 | 12.8K | 14,000 | — | ↗ |
| 2016-12-08 | Jones Robert B | Director / Officer | A-Award | A | Stock Options | 47,000 | 0.92 | 43.0K | 47,000 | — | ↗ |
| 2016-12-08 | EMIGH JAMES F | Officer | A-Award | A | Stock Options | 14,000 | 0.92 | 12.8K | 14,000 | — | ↗ |
| 2016-12-08 | CLEMENS PETER A | Officer | A-Award | A | Stock Options | 34,000 | 0.92 | 31.1K | 34,000 | — | ↗ |
| 2016-12-08 | Brzeczko Albert W | Officer | A-Award | A | Stock Options | 35,000 | 0.92 | 32.0K | 35,000 | — | ↗ |
| 2016-01-04 | WESSON BRUCE F | Director | M-Exempt | D | Restricted Stock Units | 10,309 | 0.00 | — | 0 | — | ↗ |
| 2016-01-04 | THANGARAJ IMMANUEL | Director | M-Exempt | D | Restricted Stock Units | 6,185 | 0.00 | — | 0 | — | ↗ |
| 2016-01-04 | SKELLY WILLIAM G | Director | A-Award | A | Restricted Stock Units | 22,026 | 0.00 | — | 22,026 | — | ↗ |
| 2016-01-04 | ROSS GEORGE K | Director | M-Exempt | D | Restricted Stock Units | 8,074 | 0.00 | — | 2,450 | — | ↗ |
| 2015-12-10 | Seiser Robert A | Officer | A-Award | A | Stock Options | 20,000 | 2.01 | 40.2K | 20,000 | — | ↗ |
| 2015-12-10 | Rivet J Bradley | Officer | A-Award | A | Stock Options | 20,000 | 2.01 | 40.2K | 20,000 | — | ↗ |
| 2015-12-10 | Jones Robert B | Director / Officer | A-Award | A | Stock Options | 70,000 | 2.01 | 140.7K | 70,000 | — | ↗ |
| 2015-12-10 | EMIGH JAMES F | Officer | A-Award | A | Stock Options | 20,000 | 2.01 | 40.2K | 20,000 | — | ↗ |
| 2015-12-10 | CLEMENS PETER A | Officer | A-Award | A | Stock Options | 50,000 | 2.01 | 100.5K | 50,000 | — | ↗ |
| 2015-12-10 | Brzeczko Albert W | Officer | A-Award | A | Stock Options | 50,000 | 2.01 | 100.5K | 50,000 | — | ↗ |
| 2015-06-17 | CLAUDIUS LLC | 10% Owner | S-Sale | D | Common Stock | 3,900 | 1.05 | 4.1K | 10,978,674 | — | ↗ |
| 2015-06-16 | CLAUDIUS LLC | 10% Owner | S-Sale | D | Common Stock | 100,923 | 1.08 | 109.4K | 10,982,574 | — | ↗ |
| 2015-01-12 | CLAUDIUS LLC | 10% Owner | S-Sale | D | Common Stock | 35,000 | 0.64 | 22.5K | 11,083,497 | — | ↗ |
| 2015-01-09 | CLAUDIUS LLC | 10% Owner | S-Sale | D | Common Stock | 36,000 | 0.65 | 23.4K | 11,118,497 | — | ↗ |
| 2015-01-08 | CLAUDIUS LLC | 10% Owner | S-Sale | D | Common Stock | 100,000 | 0.60 | 60.2K | 11,154,497 | — | ↗ |
| 2015-01-02 | WESSON BRUCE F | Director | M-Exempt | D | Restricted Stock Units | 36,764 | 0.00 | — | 0 | — | ↗ |
| 2015-01-02 | THANGARAJ IMMANUEL | Director | D-Return | D | Restricted Stock Units | 14,705 | 0.00 | — | 0 | — | ↗ |
| 2015-01-02 | SKELLY WILLIAM G | Director | D-Return | D | Restricted Stock Units | 7,352 | 0.00 | — | 0 | — | ↗ |
| 2015-01-02 | ROSS GEORGE K | Director | M-Exempt | A | Common Stock | 11,030 | 0.01 | 110.30 | 14,030 | — | ↗ |
| 2014-12-11 | Seiser Robert A | Officer | A-Award | A | Stock Options | 54,000 | 0.52 | 28.1K | 54,000 | — | ↗ |
| 2014-12-11 | Rivet J Bradley | Officer | A-Award | A | Stock Options | 81,000 | 0.52 | 42.1K | 81,000 | — | ↗ |
| 2014-12-11 | Jones Robert B | Director / Officer | A-Award | A | Stock Options | 252,000 | 0.52 | 131.0K | 252,000 | — | ↗ |
| 2014-12-11 | EMIGH JAMES F | Officer | A-Award | A | Stock Options | 54,000 | 0.52 | 28.1K | 54,000 | — | ↗ |
| 2014-12-11 | CLEMENS PETER A | Officer | A-Award | A | Stock Options | 180,000 | 0.52 | 93.6K | 180,000 | — | ↗ |
| 2014-12-11 | Brzeczko Albert W | Officer | A-Award | A | Stock Options | 144,000 | 0.52 | 74.9K | 144,000 | — | ↗ |
| 2014-05-22 | SKELLY WILLIAM G | Director | S-Sale | D | Common Stock | 4,600 | 1.23 | 5.7K | 5,000 | — | ↗ |
| 2014-05-20 | SKELLY WILLIAM G | Director | S-Sale | D | Common Stock | 217 | 1.22 | 264.74 | 14,383 | — | ↗ |
| 2014-05-19 | Rivet J Bradley | Officer | P-Purchase | A | Common Stock | 2,000 | 1.23 | 2.5K | 2,000 | — | ↗ |
| 2014-05-19 | Brzeczko Albert W | Officer | P-Purchase | A | Common Stock | 2,000 | 1.20 | 2.4K | 26,000 | — | ↗ |
| 2014-05-16 | WESSON BRUCE F | Director | P-Purchase | A | Common Stock | 9,900 | 1.18 | 11.7K | 94,914 | — | ↗ |
| 2014-05-16 | EMIGH JAMES F | Officer | P-Purchase | A | Common Stock | 15,000 | 1.21 | 18.1K | 198,304 | — | ↗ |
| 2014-05-16 | CLEMENS PETER A | Officer | P-Purchase | D | Common Stock | 3,000 | 1.21 | 3.6K | 275,918 | — | ↗ |
| 2014-05-15 | WESSON BRUCE F | Director | P-Purchase | A | Common Stock | 10,000 | 1.11 | 11.1K | 74,914 | — | ↗ |
| 2014-05-14 | SKELLY WILLIAM G | Director | S-Sale | D | Common Stock | 2,900 | 1.21 | 3.5K | 14,600 | — | ↗ |
| 2014-05-12 | SKELLY WILLIAM G | Director | S-Sale | D | Common Stock | 5,000 | 1.25 | 6.3K | 17,500 | — | ↗ |
| 2014-05-08 | SKELLY WILLIAM G | Director | S-Sale | D | Common Stock | 2,500 | 1.30 | 3.3K | 22,500 | — | ↗ |
| 2014-05-01 | WESSON BRUCE F | Director | A-Award | A | Restricted Stock Units | 36,764 | 0.00 | — | 36,764 | — | ↗ |
| 2014-05-01 | THANGARAJ IMMANUEL | Director | A-Award | A | Restricted Stock Units | 36,764 | 0.00 | — | 36,764 | — | ↗ |
| 2014-05-01 | SKELLY WILLIAM G | Director | A-Award | A | Restricted Stock Units | 36,764 | 0.00 | — | 36,764 | — | ↗ |
| 2014-05-01 | ROSS GEORGE K | Director | A-Award | A | Restricted Stock Units | 36,764 | 0.00 | — | 36,764 | — | ↗ |
| 2014-03-03 | CLAUDIUS LLC | 10% Owner | S-Sale | D | Common Stock | 2,500 | 2.00 | 5.0K | 11,128,618 | — | ↗ |
| 2014-02-28 | CLAUDIUS LLC | 10% Owner | S-Sale | D | Common Stock | 21,602 | 2.01 | 43.3K | 11,256,998 | — | ↗ |
| 2014-02-28 | CARE CAPITAL II LLC | 10% Owner | S-Sale | D | Common Stock | 51,204 | 2.04 | 104.5K | 4,058,337 | — | ↗ |
| 2014-02-27 | CLEMENS PETER A | Officer | F-InKind | D | Common Stock | 883 | 2.03 | 1.8K | 272,913 | — | ↗ |
| 2014-02-27 | CLAUDIUS LLC | 10% Owner | S-Sale | D | Common Stock | 192,479 | 2.04 | 392.9K | 11,278,598 | — | ↗ |
| 2014-02-27 | CARE CAPITAL II LLC | 10% Owner | S-Sale | D | Common Stock | 179,968 | 2.04 | 367.1K | 4,109,541 | — | ↗ |
| 2014-02-26 | CLAUDIUS LLC | 10% Owner | S-Sale | D | Common Stock | 5,000 | 1.95 | 9.8K | 11,471,078 | — | ↗ |
| 2014-02-24 | CLAUDIUS LLC | 10% Owner | S-Sale | D | Common Stock | 43,747 | 1.97 | 86.0K | 11,482,379 | — | ↗ |
| 2014-02-21 | CLAUDIUS LLC | 10% Owner | S-Sale | D | Common Stock | 272 | 1.95 | 530.40 | 11,526,126 | — | ↗ |
| 2014-02-18 | CLAUDIUS LLC | 10% Owner | S-Sale | D | Common Stock | 2,200 | 1.95 | 4.3K | 11,526,398 | — | ↗ |
| 2014-02-18 | CARE CAPITAL II LLC | 10% Owner | S-Sale | D | Common Stock | 20,032 | 2.04 | 40.9K | 4,289,509 | — | ↗ |
| 2014-01-24 | EMIGH JAMES F | Officer | M-Exempt | A | Common Stock | 6,225 | 1.30 | 8.1K | 183,304 | — | ↗ |
| 2014-01-16 | Seiser Robert A | Officer | M-Exempt | D | Stock Options | 6,225 | 1.30 | 8.1K | 0 | — | ↗ |
| 2014-01-02 | THANGARAJ IMMANUEL | Director | M-Exempt | A | Common Stock | 22,059 | 0.01 | 220.59 | 22,059 | — | ↗ |
| 2014-01-01 | Seiser Robert A | Officer | F-InKind | D | Common Stock | 283 | 1.67 | 472.61 | 109,641 | — | ↗ |
| 2014-01-01 | Jones Robert B | Director / Officer | F-InKind | D | Common Stock | 11,924 | 1.67 | 19.9K | 62,921 | — | ↗ |
| 2014-01-01 | CLEMENS PETER A | Officer | F-InKind | D | Common Stock | 704 | 1.67 | 1.2K | 327,212 | — | ↗ |
| 2013-12-17 | CLEMENS PETER A | Officer | M-Exempt | A | Common Stock | 9,375 | 1.30 | 12.2K | 335,641 | — | ↗ |
| 2013-12-12 | Seiser Robert A | Officer | A-Award | A | Stock Options | 37,500 | 1.55 | 58.1K | 37,500 | — | ↗ |
| 2013-12-12 | Rivet J Bradley | Officer | A-Award | A | Stock Options | 50,000 | 1.55 | 77.5K | 50,000 | — | ↗ |
| 2013-12-12 | Jones Robert B | Director / Officer | A-Award | A | Stock Options | 137,500 | 1.55 | 213.1K | 137,500 | — | ↗ |
| 2013-12-12 | EMIGH JAMES F | Officer | A-Award | A | Stock Options | 37,500 | 1.55 | 58.1K | 37,500 | — | ↗ |
| 2013-12-12 | CLEMENS PETER A | Officer | A-Award | A | Stock Options | 75,000 | 1.55 | 116.3K | 75,000 | — | ↗ |
| 2013-12-12 | Brzeczko Albert W | Officer | A-Award | A | Stock Options | 75,000 | 1.55 | 116.3K | 75,000 | — | ↗ |
| 2013-11-25 | Brzeczko Albert W | Officer | P-Purchase | A | Common Stock | 1,215 | 1.70 | 2.1K | 24,000 | — | ↗ |
| 2013-10-10 | CLAUDIUS LLC | 10% Owner | S-Sale | D | Common Stock | 4,200 | 2.05 | 8.6K | 11,528,598 | — | ↗ |
| 2013-10-10 | CARE CAPITAL II LLC | 10% Owner | S-Sale | D | Common Stock | 5,400 | 2.02 | 10.9K | 4,309,541 | — | ↗ |
| 2013-08-27 | SKELLY WILLIAM G | Director | S-Sale | D | Common Stock | 2,000 | 1.55 | 3.1K | 25,000 | — | ↗ |
| 2013-07-15 | CARE CAPITAL II LLC | 10% Owner | S-Sale | D | Common Stock | 31,610 | 2.04 | 64.5K | 4,314,941 | — | ↗ |
| 2013-07-03 | CARE CAPITAL II LLC | 10% Owner | S-Sale | D | Common Stock | 14,200 | 2.00 | 28.4K | 4,346,551 | — | ↗ |
| 2013-07-02 | CLAUDIUS LLC | 10% Owner | S-Sale | D | Common Stock | 200,000 | 2.15 | 430.0K | 11,532,798 | — | ↗ |
| 2013-07-02 | CARE CAPITAL II LLC | 10% Owner | S-Sale | D | Common Stock | 81,082 | 2.04 | 165.4K | 4,360,751 | — | ↗ |
| 2013-07-01 | CARE CAPITAL II LLC | 10% Owner | S-Sale | D | Common Stock | 500,000 | 2.36 | 1.18M | 4,441,833 | — | ↗ |
| 2013-06-27 | CARE CAPITAL II LLC | 10% Owner | S-Sale | D | Common Stock | 9,042 | 2.01 | 18.2K | 4,941,833 | — | ↗ |
| 2013-06-26 | CARE CAPITAL II LLC | 10% Owner | S-Sale | D | Common Stock | 28,000 | 2.02 | 56.6K | 4,950,875 | — | ↗ |
| 2013-06-25 | CARE CAPITAL II LLC | 10% Owner | S-Sale | D | Common Stock | 39,239 | 2.01 | 78.9K | 4,978,875 | — | ↗ |
| 2013-06-24 | CARE CAPITAL II LLC | 10% Owner | S-Sale | D | Common Stock | 23,000 | 2.03 | 46.7K | 5,018,114 | — | ↗ |
| 2013-06-21 | CARE CAPITAL II LLC | 10% Owner | S-Sale | D | Common Stock | 24,000 | 2.03 | 48.7K | 5,041,114 | — | ↗ |
| 2013-06-20 | CARE CAPITAL II LLC | 10% Owner | S-Sale | D | Common Stock | 36,000 | 2.02 | 72.7K | 5,065,114 | — | ↗ |
| 2013-06-19 | CARE CAPITAL II LLC | 10% Owner | S-Sale | D | Common Stock | 42,000 | 2.08 | 87.4K | 5,101,114 | — | ↗ |
| 2013-06-18 | CARE CAPITAL II LLC | 10% Owner | S-Sale | D | Common Stock | 32,000 | 2.13 | 68.2K | 5,143,114 | — | ↗ |
| 2013-06-17 | CLAUDIUS LLC | 10% Owner | S-Sale | D | Common Stock | 20,446 | 2.15 | 44.0K | 11,732,798 | — | ↗ |
| 2013-06-17 | CARE CAPITAL II LLC | 10% Owner | S-Sale | D | Common Stock | 40,000 | 2.15 | 86.0K | 5,175,114 | — | ↗ |
| 2013-06-14 | CLAUDIUS LLC | 10% Owner | S-Sale | D | Common Stock | 27,814 | 2.15 | 59.8K | 11,753,244 | — | ↗ |
| 2013-06-14 | CARE CAPITAL II LLC | 10% Owner | S-Sale | D | Common Stock | 30,000 | 2.15 | 64.5K | 5,215,114 | — | ↗ |
| 2013-06-13 | CARE CAPITAL II LLC | 10% Owner | S-Sale | D | Common Stock | 28,000 | 2.15 | 60.2K | 5,245,114 | — | ↗ |
| 2013-06-12 | CLAUDIUS LLC | 10% Owner | S-Sale | D | Common Stock | 3,469 | 2.20 | 7.6K | 11,781,058 | — | ↗ |
| 2013-06-12 | CARE CAPITAL II LLC | 10% Owner | S-Sale | D | Common Stock | 32,000 | 2.18 | 69.8K | 5,273,114 | — | ↗ |
| 2013-06-11 | CARE CAPITAL II LLC | 10% Owner | S-Sale | D | Common Stock | 22,000 | 2.17 | 47.7K | 5,305,114 | — | ↗ |
| 2013-06-10 | CLAUDIUS LLC | 10% Owner | S-Sale | D | Common Stock | 9,700 | 2.21 | 21.4K | 11,784,527 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-75.4K
Shares Outstanding
66.00M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2020 | Albert W. Brzeczko VP, Pharmaceutical Sciences of Acura Pharmaceutical Technologies, Inc. | 220.0K | — | — | — | — | — | 220.0K | 0.00% | ↗ |
| 2 | 2020 | Peter A. Clemens SVP & CFO | 200.0K | — | — | — | — | — | 200.0K | 0.00% | ↗ |
| 3 | 2020 | Robert B. Jones, President and CEO | 150.0K | — | — | — | — | — | 150.0K | 0.00% | ↗ |
| 4 | 2019 | Albert W. Brzeczko VP, Pharmaceutical Sciences of Acura Pharmaceutical Technologies, Inc. | 180.0K | — | — | — | — | — | 180.0K | 0.00% | ↗ |
| 5 | 2019 | Peter A. Clemens SVP & CFO | 164.0K | — | — | — | — | — | 164.0K | 0.00% | ↗ |
| 6 | 2019 | Robert B. Jones, President and CEO | 123.0K | — | — | — | — | — | 123.0K | 0.00% | ↗ |
| 7 | 2016 | Peter A. Clemens SVP & CFO | 393.0K | — | — | 36.2K | — | — | 429.2K | 8.44% | ↗ |
| 8 | 2016 | Albert W. Brzeczko VP, Technical Affairs of Acura Pharmaceutical Technologies, Inc. | 286.0K | — | — | 26.2K | — | — | 312.2K | 8.40% | ↗ |
| 9 | 2015 | Robert B. Jones, President and CEO since July 7, 2011, Interim President and CEO from April 28, 2011 and SVP & COO prior thereto Peter A. Clemens SVP & CFO | 392.0K | — | — | 120.7K | 215.6K | — | 728.3K | 16.57% | ↗ |
| 10 | 2015 | Robert B. Jones, President and CEO | 392.0K | — | — | 120.7K | 215.6K | — | 728.3K | 16.57% | ↗ |
| 11 | 2015 | Peter A. Clemens SVP & CFO Albert W. Brzeczko VP, Technical Affairs of Acura Pharmaceutical Technologies, Inc. | 285.0K | — | — | 86.2K | 109.7K | — | 480.9K | 17.92% | ↗ |
| 12 | 2015 | Peter A. Clemens SVP & CFO | 285.0K | — | — | 86.2K | 109.7K | — | 480.9K | 17.92% | ↗ |
| 13 | 2015 | Albert W. Brzeczko VP, Technical Affairs of Acura Pharmaceutical Technologies, Inc. | 290.0K | — | — | 86.2K | 68.5K | — | 444.7K | 19.38% | ↗ |
| 14 | 2015 | Albert W. Brzeczko VP, Technical Affairs of Acura Pharmaceutical Technologies, Inc. Robert A. Seiser VP, Treasurer & Corporate Controller | 290.0K | — | — | 86.2K | 68.5K | — | 444.7K | 19.38% | ↗ |
| 15 | 2015 | Robert A. Seiser VP, Treasurer & Corporate Controller J. Bradley Rivet, Vice President of Marketing | 175.0K | — | — | 34.5K | 35.2K | — | 244.7K | 14.09% | ↗ |
| 16 | 2015 | J. Bradley Rivet, Vice President of Marketing James F. Emigh, Vice President of Corporate Development | 175.0K | — | — | 34.5K | 30.6K | — | 240.1K | 14.36% | ↗ |
| 17 | 2015 | James F. Emigh, Vice President of Corporate Development | 175.0K | — | — | 34.5K | 21.4K | — | 230.9K | 14.93% | ↗ |
| 18 | 2014 | Robert B. Jones, President and CEO since July 7, 2011, Interim President and CEO from April 28, 2011 and SVP & COO prior thereto | 387.0K | — | — | 116.4K | — | — | 503.4K | 23.13% | ↗ |
| 19 | 2014 | Robert B. Jones, President and CEO since July 7, 2011, Interim President and CEO from April 28, 2011 and SVP & COO prior thereto Peter A. Clemens SVP & CFO | 387.0K | — | — | 116.4K | — | — | 503.4K | 23.13% | ↗ |
| 20 | 2014 | Peter A. Clemens SVP & CFO Albert W. Brzeczko VP, Technical Affairs of Acura Pharmaceutical Technologies, Inc. | 280.0K | — | — | 83.2K | — | — | 363.2K | 22.90% | ↗ |
| 21 | 2014 | Peter A. Clemens SVP & CFO | 280.0K | — | — | 83.2K | — | — | 363.2K | 22.90% | ↗ |
| 22 | 2014 | Albert W. Brzeczko VP, Technical Affairs of Acura Pharmaceutical Technologies, Inc. | 285.0K | — | — | 66.5K | — | — | 351.5K | 18.93% | ↗ |
| 23 | 2014 | Albert W. Brzeczko VP, Technical Affairs of Acura Pharmaceutical Technologies, Inc. Robert A. Seiser VP, Treasurer & Corporate Controller | 285.0K | — | — | 66.5K | — | — | 351.5K | 18.93% | ↗ |
| 24 | 2014 | J. Bradley Rivet, Vice President of Marketing James F. Emigh, Vice President of Corporate Development | 172.0K | — | — | 37.4K | — | — | 209.4K | 17.87% | ↗ |
| 25 | 2014 | J. Bradley Rivet, Vice President of Marketing | 172.0K | — | — | 37.4K | — | — | 209.4K | 17.87% | ↗ |
| 26 | 2014 | Robert A. Seiser VP, Treasurer & Corporate Controller J. Bradley Rivet, Vice President of Marketing | 172.0K | — | — | 24.9K | — | — | 196.9K | 12.67% | ↗ |
| 27 | 2014 | Robert A. Seiser VP, Treasurer & Corporate Controller | 172.0K | — | — | 24.9K | — | — | 196.9K | 12.67% | ↗ |
| 28 | 2014 | James F. Emigh, Vice President of Corporate Development | 172.0K | — | — | 24.9K | — | — | 196.9K | 12.67% | ↗ |
| 29 | 2013 | Robert B. Jones, President and CEO since July 7, 2011, Interim President and CEO from April 28, 2011 and SVP & COO prior thereto | 383.0K | — | — | 197.5K | 126.4K | — | 706.9K | 27.94% | ↗ |
| 30 | 2013 | Peter A. Clemens SVP & CFO Albert W. Brzeczko VP, Technical Affairs of Acura Pharmaceutical Technologies, Inc. | 282.0K | — | — | 107.8K | 50.8K | — | 440.6K | 24.46% | ↗ |
| 31 | 2013 | Albert W. Brzeczko VP, Technical Affairs of Acura Pharmaceutical Technologies, Inc. | 282.0K | — | — | 107.8K | 50.8K | — | 440.6K | 24.46% | ↗ |
| 32 | 2013 | Robert B. Jones, President and CEO since July 7, 2011, Interim President and CEO from April 28, 2011 and SVP & COO prior thereto Peter A. Clemens SVP & CFO | 219.0K | — | — | 107.8K | 72.3K | — | 399.1K | 27.00% | ↗ |
| 33 | 2013 | Peter A. Clemens SVP & CFO | 219.0K | — | — | 107.8K | 72.3K | — | 399.1K | 27.00% | ↗ |
| 34 | 2013 | Albert W. Brzeczko VP, Technical Affairs of Acura Pharmaceutical Technologies, Inc. Robert A. Seiser VP, Treasurer & Corporate Controller | 170.0K | — | — | 53.9K | 30.6K | — | 254.5K | 21.17% | ↗ |
| 35 | 2013 | Robert A. Seiser VP, Treasurer & Corporate Controller | 170.0K | — | — | 53.9K | 30.6K | — | 254.5K | 21.17% | ↗ |
| 36 | 2013 | Robert A. Seiser VP, Treasurer & Corporate Controller J. Bradley Rivet, Vice President of Marketing | 155.0K | — | — | 71.8K | 16.5K | — | 243.3K | 29.52% | ↗ |
| 37 | 2013 | J. Bradley Rivet, Vice President of Marketing | 155.0K | — | — | 71.8K | 16.5K | — | 243.3K | 29.52% | ↗ |
| 38 | 2013 | James F. Emigh, Vice President of Corporate Development | 170.0K | — | — | 53.9K | 18.1K | — | 242.0K | 22.27% | ↗ |
| 39 | 2013 | J. Bradley Rivet, Vice President of Marketing James F. Emigh, Vice President of Corporate Development | 170.0K | — | — | 53.9K | 18.1K | — | 242.0K | 22.27% | ↗ |
| 40 | 2012 | Robert B. Jones, President and CEO since July 7, 2011, Interim President and CEO from April 28, 2011 and SVP & COO prior thereto | 383.0K | — | — | 219.4K | — | — | 602.4K | 36.42% | ↗ |
| 41 | 2012 | Albert W. Brzeczko VP, Technical Affairs Robert A. Seiser VP, Treasurer & Corporate Controller | 282.0K | — | — | 170.6K | — | — | 452.6K | 37.69% | ↗ |
| 42 | 2012 | Albert W. Brzeczko VP, Technical Affairs of Acura Pharmaceutical Technologies, Inc. | 282.0K | — | — | 170.6K | — | — | 452.6K | 37.69% | ↗ |
| 43 | 2012 | Peter A. Clemens SVP & CFO Albert W. Brzeczko VP, Technical Affairs of Acura Pharmaceutical Technologies, Inc. | 282.0K | — | — | 170.6K | — | — | 452.6K | 37.69% | ↗ |
| 44 | 2012 | Peter A. Clemens SVP & CFO | 219.0K | — | — | 121.9K | — | — | 340.9K | 35.75% | ↗ |
| 45 | 2012 | Robert B. Jones, President and CEO since July 7, 2011, Interim President and CEO from April 28, 2011 and SVP & COO prior thereto Peter A. Clemens SVP & CFO | 219.0K | — | — | 121.9K | — | — | 340.9K | 35.75% | ↗ |
| 46 | 2012 | Peter A. Clemens SVP & CFO Albert W. Brzeczko VP, Technical Affairs | 219.0K | — | — | 121.9K | — | — | 340.9K | 35.75% | ↗ |
| 47 | 2012 | J. Bradley Rivet, Vice President of Marketing James F. Emigh, Vice President of Corporate Development | 170.0K | — | — | 97.5K | — | — | 267.5K | 36.45% | ↗ |
| 48 | 2012 | Robert A. Seiser VP, Treasurer & Corporate Controller | 170.0K | — | — | 97.5K | — | — | 267.5K | 36.45% | ↗ |
| 49 | 2012 | Albert W. Brzeczko VP, Technical Affairs of Acura Pharmaceutical Technologies, Inc. Robert A. Seiser VP, Treasurer & Corporate Controller | 170.0K | — | — | 97.5K | — | — | 267.5K | 36.45% | ↗ |
| 50 | 2012 | James Emigh, VP Corporate Development | 170.0K | — | — | 97.5K | — | — | 267.5K | 36.45% | ↗ |
| 51 | 2012 | J. Bradley Rivet, Vice President of Marketing | 155.0K | — | — | 97.5K | — | — | 252.5K | 38.61% | ↗ |
| 52 | 2012 | Robert A. Seiser VP, Treasurer & Corporate Controller J. Bradley Rivet, Vice President of Marketing | 155.0K | — | — | 97.5K | — | — | 252.5K | 38.61% | ↗ |
| 53 | 2011 | Robert B. Jones, President and CEO since July 7, 2011, Interim President and CEO from April 28, 2011 and SVP & COO prior thereto Andrew D. Reddick President & CEO until April 28, 2011 | 336.3K | 138.8K | — | 278.0K | — | — | 753.1K | 36.91% | ↗ |
| 54 | 2011 | Robert B. Jones, President and CEO since July 7, 2011, Interim President and CEO from April 28, 2011 and SVP & COO prior thereto | 336.3K | 138.8K | — | 278.0K | — | — | 753.1K | 36.91% | ↗ |
| 55 | 2011 | Albert W. Brzeczko VP, Technical Affairs (commenced employment February 9, 2009) Robert A. Seiser VP, Treasurer & Corporate Controller | 273.0K | 41.1K | — | 122.0K | — | — | 436.1K | 27.98% | ↗ |
| 56 | 2011 | Peter A. Clemens SVP & CFO Albert W. Brzeczko VP, Technical Affairs of Acura Pharmaceutical Technologies, Inc. | 273.0K | 41.1K | — | 122.0K | — | — | 436.1K | 27.98% | ↗ |
| 57 | 2011 | Albert W. Brzeczko VP, Technical Affairs | 273.0K | 41.1K | — | 122.0K | — | — | 436.1K | 27.98% | ↗ |
| 58 | 2011 | Peter A. Clemens SVP & CFO Albert W. Brzeczko VP, Technical Affairs (commenced employment February 9, 2009) | 211.5K | 96.5K | — | 122.0K | — | — | 430.0K | 28.37% | ↗ |
| 59 | 2011 | Robert B. Jones, President and CEO since July 7, 2011, Interim President and CEO from April 28, 2011 and SVP & COO prior thereto Peter A. Clemens SVP & CFO | 211.5K | 96.5K | — | 122.0K | — | — | 430.0K | 28.37% | ↗ |
| 60 | 2011 | Peter A. Clemens SVP & CFO | 211.5K | 96.5K | — | 122.0K | — | — | 430.0K | 28.37% | ↗ |
| 61 | 2011 | Robert A. Seiser VP, Treasurer & Corporate Controller J. Bradley Rivet, Vice President of Marketing | 32.8K | 6.2K | — | 314.0K | — | — | 353.0K | 88.95% | ↗ |
| 62 | 2011 | J. Bradley Rivet, VP, Marketing (commenced employment October 3, 2011) | 32.8K | 6.2K | — | 314.0K | — | — | 353.0K | 88.95% | ↗ |
| 63 | 2011 | Robert A. Seiser VP, Treasurer & Corporate Controller | 165.0K | 33.5K | — | 122.0K | — | — | 320.5K | 38.07% | ↗ |
| 64 | 2011 | Albert W. Brzeczko VP, Technical Affairs of Acura Pharmaceutical Technologies, Inc. Robert A. Seiser VP, Treasurer & Corporate Controller | 165.0K | 33.5K | — | 122.0K | — | — | 320.5K | 38.07% | ↗ |
| 65 | 2011 | Andrew D. Reddick President & CEO until April 28, 2011 Peter A. Clemens SVP & CFO | 130.5K | 121.9K | — | — | — | — | 252.4K | 0.00% | ↗ |
| 66 | 2010 | Robert B. Jones, SVP & COO (commenced employment April 7, 2008) Albert W. Brzeczko VP, Technical Affairs (commenced employment February 9, 2009) | 300.0K | 99.0K | — | 711.0K | — | — | 1.11M | 64.05% | ↗ |
| 67 | 2010 | Robert B. Jones, President and CEO since July 7, 2011, Interim President and CEO from April 28, 2011 and SVP & COO prior thereto | 300.0K | 99.0K | — | 711.0K | — | — | 1.11M | 64.05% | ↗ |
| 68 | 2010 | Andrew D. Reddick President & CEO Peter A. Clemens SVP & CFO | 377.0K | 124.0K | — | 237.0K | — | — | 738.0K | 32.11% | ↗ |
| 69 | 2010 | Andrew D. Reddick President & CEO until April 28, 2011 | 377.0K | 124.0K | — | 237.0K | — | — | 738.0K | 32.11% | ↗ |
| 70 | 2010 | Peter A. Clemens SVP & CFO Robert B. Jones, SVP & COO (commenced employment April 7, 2008) | 211.5K | 88.0K | — | 113.8K | — | — | 413.3K | 27.53% | ↗ |
| 71 | 2010 | Robert B. Jones, President and CEO since July 7, 2011, Interim President and CEO from April 28, 2011 and SVP & COO prior thereto Peter A. Clemens SVP & CFO | 211.5K | 88.0K | — | 113.8K | — | — | 413.3K | 27.53% | ↗ |
| 72 | 2010 | Peter A. Clemens SVP & CFO | 211.5K | 88.0K | — | 113.8K | — | — | 413.3K | 27.53% | ↗ |
| 73 | 2010 | Albert W. Brzeczko VP, Technical Affairs (commenced employment February 9, 2009) Robert A. Seiser VP, Treasurer & Corporate Controller | 273.0K | 47.0K | — | 91.0K | — | — | 411.0K | 22.14% | ↗ |
| 74 | 2010 | Peter A. Clemens SVP & CFO Albert W. Brzeczko VP, Technical Affairs | 273.0K | 47.0K | — | 91.0K | — | — | 411.0K | 22.14% | ↗ |
| 75 | 2010 | Albert W. Brzeczko VP, Technical Affairs (commenced employment February 9, 2009) | 273.0K | 47.0K | — | 91.0K | — | — | 411.0K | 22.14% | ↗ |
| 76 | 2010 | Albert W. Brzeczko VP, Technical Affairs Robert A. Seiser VP, Treasurer & Corporate Controller | 165.0K | 28.0K | — | 91.0K | — | — | 284.0K | 32.04% | ↗ |
| 77 | 2010 | Robert A. Seiser VP, Treasurer & Corporate Controller | 165.0K | 28.0K | — | 91.0K | — | — | 284.0K | 32.04% | ↗ |
| 78 | 2009 | Andrew D. Reddick President & CEO | 365.0K | 140.0K | 533.8K | 1.50M | — | — | 2.54M | 80.15% | ↗ |
| 79 | 2009 | Andrew D. Reddick President & CEO Peter A. Clemens SVP & CFO | 365.0K | 140.0K | 533.8K | 1.50M | — | — | 2.54M | 80.15% | ↗ |
| 80 | 2009 | Robert B. Jones, President and CEO since July 7, 2011, Interim President and CEO from April 28, 2011 and SVP & COO prior thereto Andrew D. Reddick President & CEO until April 28, 2011 | 365.0K | 140.0K | 533.8K | 1.50M | — | — | 2.54M | 80.15% | ↗ |
| 81 | 2009 | Robert B. Jones, SVP & COO (commenced employment April 7, 2008) | 290.0K | 112.0K | 431.5K | 963.0K | — | — | 1.80M | 77.62% | ↗ |
| 82 | 2009 | Robert B. Jones, President and CEO since July 7, 2011, Interim President and CEO from April 28, 2011 and SVP & COO prior thereto | 290.0K | 112.0K | 431.5K | 963.0K | — | — | 1.80M | 77.62% | ↗ |
| 83 | 2009 | Peter A. Clemens SVP & CFO Robert B. Jones, SVP & COO (commenced employment April 7, 2008) | 205.0K | 74.0K | 188.4K | 722.3K | — | — | 1.19M | 76.55% | ↗ |
| 84 | 2009 | Andrew D. Reddick President & CEO until April 28, 2011 Peter A. Clemens SVP & CFO | 205.0K | 74.0K | 188.4K | 722.3K | — | — | 1.19M | 76.55% | ↗ |
| 85 | 2009 | Peter A. Clemens SVP & CFO | 205.0K | 74.0K | 188.4K | 722.3K | — | — | 1.19M | 76.55% | ↗ |
| 86 | 2009 | Robert B. Jones, SVP & COO (commenced employment April 7, 2008) Albert W. Brzeczko VP, Technical Affairs (commenced employment February 9, 2009) | 234.4K | 73.0K | 136.6K | 524.0K | — | — | 968.0K | 68.24% | ↗ |
| 87 | 2009 | Peter A. Clemens SVP & CFO Albert W. Brzeczko VP, Technical Affairs (commenced employment February 9, 2009) | 234.4K | 73.0K | 136.6K | 524.0K | — | — | 968.0K | 68.24% | ↗ |
| 88 | 2009 | Robert A. Seiser VP, Treasurer & Corporate Controller | 160.0K | 21.5K | 150.7K | 577.8K | — | — | 910.0K | 80.06% | ↗ |
| 89 | 2009 | Albert W. Brzeczko VP, Technical Affairs (commenced employment February 9, 2009) Robert A. Seiser VP, Treasurer & Corporate Controller | 160.0K | 21.5K | 150.7K | 577.8K | — | — | 910.0K | 80.06% | ↗ |
| 90 | 2008 | Andrew D. Reddick President & CEO | 365.0K | 328.5K | — | 2.37M | — | — | 3.06M | 77.36% | ↗ |
| 91 | 2008 | Ron J. Spivey SVP and Chief Scientific Officer | 315.0K | 630.0K | — | 442.0K | — | — | 1.39M | 31.87% | ↗ |
| 92 | 2008 | Peter A. Clemens SVP & CFO Robert B. Jones, SVP & COO (commenced employment April 7, 2008) | 211.9K | 130.5K | 282.6K | 685.5K | — | — | 1.31M | 73.87% | ↗ |
| 93 | 2008 | Andrew D. Reddick President & CEO Peter A. Clemens SVP & CFO | 205.0K | 102.5K | — | 947.8K | — | — | 1.26M | 75.50% | ↗ |
| 94 | 2008 | Peter A. Clemens SVP & CFO | 205.0K | 102.5K | — | 947.8K | — | — | 1.26M | 75.50% | ↗ |
| 95 | 2008 | Robert B. Jones SVP & COO (commenced employment April 7, 2008) Robert A. Seiser VP, Treasurer & Corporate Controller | 211.9K | 130.5K | 173.0K | 544.0K | — | — | 1.06M | 67.68% | ↗ |
| 96 | 2008 | Albert W. Brzeczko VP, Technical Affairs (commenced employment February 9, 2009) Robert A. Seiser VP, Treasurer & Corporate Controller | 160.0K | 56.0K | — | 758.3K | — | — | 974.3K | 77.83% | ↗ |
| 97 | 2008 | Robert A. Seiser VP, Treasurer & Corporate Controller | 160.0K | 56.0K | — | 758.3K | — | — | 974.3K | 77.83% | ↗ |
| 98 | 2008 | Peter A. Clemens SVP & CFO Ron J. Spivey SVP and Chief Scientific Officer | 205.0K | 102.5K | — | 276.0K | — | — | 583.5K | 47.30% | ↗ |
| 99 | 2007 | Ron J. Spivey SVP and Chief Scientific Officer | 260.0K | 650.0K | 211.0K | — | — | — | 1.12M | 18.82% | ↗ |
| 100 | 2007 | Ron J. Spivey SVP and Chief Scientific Officer James F. Emigh VP, Marketing & Administration | 260.0K | 650.0K | 211.0K | — | — | — | 1.12M | 18.82% | ↗ |
| 101 | 2007 | Andrew D. Reddick President & CEO | 300.0K | 850.0K | — | — | — | — | 1.04M | 0.00% | ↗ |
| 102 | 2007 | Peter A. Clemens SVP & CFO | 180.0K | 180.0K | 141.0K | 11.0K | — | — | 512.0K | 29.69% | ↗ |
| 103 | 2007 | Peter A. Clemens SVP & CFO Ron J. Spivey SVP and Chief Scientific Officer | 180.0K | 180.0K | 141.0K | 11.0K | — | — | 512.0K | 29.69% | ↗ |
| 104 | 2007 | Andrew D. Reddick President & CEO Peter A. Clemens SVP & CFO | 180.0K | 180.0K | — | — | — | — | 360.0K | 0.00% | ↗ |
| 105 | 2007 | Robert A. Seiser VP, Treasurer & Corporate Controller | 133.0K | 140.0K | 53.0K | 7.0K | — | — | 333.0K | 18.02% | ↗ |
| 106 | 2007 | Robert A. Seiser VP, Corporate Controller & Treasurer | 133.0K | 140.0K | 53.0K | 7.0K | — | — | 333.0K | 18.02% | ↗ |
| 107 | 2007 | James F. Emigh VP, Marketing & Administration Robert A. Seiser VP, Corporate Controller & Treasurer | 140.0K | 140.0K | 44.0K | 7.0K | — | — | 331.0K | 15.41% | ↗ |
| 108 | 2007 | Albert W. Brzeczko VP, Technical Affairs (commenced employment February 9, 2009) Robert A. Seiser VP, Treasurer & Corporate Controller | 133.0K | 140.0K | — | — | — | — | 273.0K | 0.00% | ↗ |
| 109 | 2006 | Andrew D. Reddick President & CEO | 300.0K | — | 1.38M | 77.0K | — | — | 1.75M | 82.88% | ↗ |
| 110 | 2006 | Peter A. Clemens SVP & CFO Ron J. Spivey SVP and Chief Scientific Officer | 260.0K | — | 1.11M | 166.0K | — | — | 1.54M | 83.07% | ↗ |
| 111 | 2006 | Andrew D. Reddick President & CEO Peter A. Clemens SVP & CFO | 180.0K | — | 733.0K | 23.0K | — | — | 936.0K | 80.77% | ↗ |
| 112 | 2006 | James F. Emigh VP, Marketing & Administration Robert A. Seiser VP, Corporate Controller & Treasurer | 133.0K | — | 275.0K | 16.0K | — | — | 424.0K | 68.63% | ↗ |
| 113 | 2006 | Robert B. Jones SVP & COO (commenced employment April 7, 2008) Robert A. Seiser VP, Treasurer & Corporate Controller | 133.0K | — | 275.0K | 16.0K | — | — | 424.0K | 68.63% | ↗ |
| 114 | 2006 | Ron J. Spivey SVP and Chief Scientific Officer James F. Emigh VP, Marketing & Administration | 140.0K | — | 229.0K | 16.0K | — | — | 385.0K | 63.64% | ↗ |
| 115 | 2005 | Ron J. Spivey Senior Vice President and Chief Scientific Officer | 260.0K | — | 12.73M | — | — | — | 12.99M | 98.00% | ↗ |
| 116 | 2005 | Andrew D. Reddick President and Chief Executive Officer | 300.0K | — | 10.91M | — | — | — | 11.21M | 97.32% | ↗ |
| 117 | 2005 | Peter A. Clemens Senior Vice President and Chief Financial Officer | 180.0K | — | 5.82M | — | — | 9.0K | 6.01M | 96.85% | ↗ |
| 118 | 2005 | Robert A. Seiser Vice President, Corporate Controller and Treasurer | 132.9K | — | 2.18M | — | — | — | 2.32M | 94.26% | ↗ |
| 119 | 2005 | James F. Emigh Vice President/Marketing and Administration | 140.0K | — | 1.82M | — | — | — | 1.96M | 92.85% | ↗ |
| 120 | 2004 | Andrew D. Reddick President and Chief Executive Officer | 305.8K | 60.0K | 8.75M | — | — | — | 9.12M | 95.99% | ↗ |
| 121 | 2004 | Ron J. Spivey Senior Vice President and Chief Scientific Officer | 190.0K | — | 3.00M | — | — | — | 3.19M | 94.04% | ↗ |
| 122 | 2004 | Peter A. Clemens Senior Vice President and Chief Financial Officer | 172.8K | 60.0K | 375.0K | — | — | 9.0K | 616.8K | 60.80% | ↗ |
| 123 | 2004 | James F. Emigh Vice President/Marketing and Administration | 137.7K | 50.0K | 249.0K | — | — | 4.2K | 440.9K | 56.48% | ↗ |
| 124 | 2004 | Robert A. Seiser Vice President, Corporate Controller and Treasurer | 123.1K | 50.0K | 249.0K | — | — | 4.5K | 426.6K | 58.37% | ↗ |
| 125 | 2003 | Peter A. Clemens Senior Vice President and Chief Financial Officer | 146.0K | 60.0K | — | — | — | 9.0K | 215.0K | 0.00% | ↗ |
| 126 | 2003 | James F. Emigh Vice President/Marketing and Administration | 127.8K | — | — | — | — | 4.2K | 132.0K | 0.00% | ↗ |
| 127 | 2003 | Robert A. Seiser Vice President, Corporate Controller and Treasurer | 110.9K | 7.0K | — | — | — | 4.5K | 122.4K | 0.00% | ↗ |
| 128 | 2003 | Andrew D. Reddick President and Chief Executive Officer | 96.9K | — | — | — | — | — | 96.9K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Robert A. Seiser | Chief Financial Officer, Senior Vice President, Treasurer & Corporate Controller | 210.2K | male |
| Robert Jones | Chief Executive Officer, President & Director | 150.0K | male |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ACUR
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
